Top Markets
#1 ONFA ONFA +225.03%
#2 Resolv wstUSR Resolv wstUSR +198.11%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 NKN NKN +36.62%
#6 DeAgentAI DeAgentAI +32.88%
#7 StakeStone StakeStone +27.06%
#8 BLOCKv BLOCKv +26.09%
#9 KONET KONET +22.11%
#10 OpenVPP OpenVPP +21.99%
Coin of the day
ONFA ONFA
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classifica tra le azioni #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Prezzo delle azioni
$0.5275
Capitalizzazione di mercato
$1.25M
Variazione (1 giorno)
-3.56%
Variazione (1 anno)
-83.77%
Paese
US
Scambia Ensysce Biosciences, Inc. (ENSC)

Categoria

Healthcare
Utile per Ensysce Biosciences, Inc. (ENSC)
Utile nel Sep 2025 TTM: $-10.97M
Secondo gli ultimi rapporti finanziari di Ensysce Biosciences, Inc., gli utili attuali della società sono $-10.97M. Nel 2023, la società ha registrato un utile di $-10.63M, un aumento rispetto a agli utili del 2022, che erano di $-24.21M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Ensysce Biosciences, Inc. dal 2017 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-10.97M 37.39%
2024 $-7.99M -24.84%
2023 $-10.63M -56.10%
2022 $-24.21M -16.94%
2021 $-29.15M 18,017.11%
2020 $-160.88K -98.41%
2019 $-10.10M -477.51%
2018 $2.68M -9,810.43%
2017 $-27.56K 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -186,530.54%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -42,414.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -47,768.53%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,581.29%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -14,811.33%
AU